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Abstract 
Focal adhesion kinase (FA}O, a non-receptor protein tyrosine kinase, becomes activated and phosphorylated on tymsine in cells 
transformed with v-src. By cytoimmunofluorescence a sub-fraction of the p85 subunit of phosphoinositide 3-kinase (PI 3-kinase) 
localized in focal adhesion plaques. We examined the possibility that FAK associates with PI 3-kinase. In fibroblasts transformed with 
polyoma middle t, PI 3-kinase activity co-immunoprecipitated with pp125 FAK using two different antibodies against his protein. 
PP125 FAK from middle t-transformed cells associated with a glutathione-S-transferase fu ion protein containing the 85-kDa subunit of 
phosphatidylinositol 3-kinase. Both of the SH2 domains and the SH3 domain of p85 also formed complexes with pp125 yAK in vitro. 
Phosphopeptides that bind to the SH2 domains completely blocked the binding of full-length p85 to pp125 ~AK, while a peptide that binds 
to the SH3 domain was ineffective, indicating that the association between p85 and pp125 FAK is mediated by the SH2 domains of p85. 
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1. Introduction 
Focal adhesion kinase (FAK) was first discovered as a 
125-kDa focal adhesion plaque-associated protein that be- 
comes tyrosine phosphorylated in v-src-transformed chick 
embryo fibroblasts [1,2]. Cloning and sequencing of the 
cDNA revealed that FAK is a novel protein-tyrosine ki- 
nase. Unlike the src-family of tyrosine kinases it lacks 
src-homology 2 (SH2) or src-homology 3 (SH3) domains 
or acylation sites [3,4]. FAK contains sites of tyrosine 
phosphorylation, in the amino- and carboxy terminal do- 
mains, that mediate association with the SH2 domain of 
activated pp60 src [5,7] or SH2 domain of GRB2 [8], 
respectively. In addition it has a carboxy-terminal region, 
named FAT (for focal adhesion targeting), that mediates 
association with focal adhesion plaques [9]. 
Abbreviations: FAK, focal adhesion kinase; GST, glutathione-S-trans- 
ferase; Ptdlns, phosphatidylinositol; PI 3-kinase, phosphoinositide 3-
kinase; SH2, src-homology 2; SH3, src-homology 3. 
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Although the function of FAK is not yet clear, it may 
play a role in anchorage-dependent cell growth. In fibrob- 
lasts the tyrosine kinase activity, measured in vitro, and the 
tyrosine-phosphorylation of FAK, are turned off when 
non-transformed cells are placed in suspension or plated 
on a non-specific ligand (such as poly-L-lysine) [10,11]. 
However, FAK can be activated in such a system by 
transformation with v-src [1,2,5]. Moreover, the tyrosine- 
phosphorylation f FAK follows the clustering of integrins 
[10,12,13] and also occurs in cells activated by neuropep- 
tides [14,15] or lysophosphatidic acid [16]. FAK is also 
activated in platelets in suspension stimulated with throm- 
bin [17] and in platelets adherent to fibrinogen or collagen 
[18,19] in a manner that depends on integrins. 
We noted that FAK contains a region in the carboxy- 
terminal domain that is predicted to interact with the SH2 
domains of the 85-kDa subunit of phosphoinositide (PI) 
3-kinase [20]. PI 3-kinase is known to be activated by a 
host of protein-tyrosine kinases (for review see Ref. [21]). 
This enzyme phosphorylates the D-3 position of phospha- 
tidylinositol (Ptdlns), Ptdlns-4-phosphate or Ptdlns-4,5- 
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bisphosphate to form Ptdlns-3-phosphate, Ptdlns-3,4-bis- 
phosphate or Ptdlns-3,4,5-trisphosphate. All three of these 
lipids are detected in mammalian cells. The levels of the 
two latter lipids have been shown to be acutely regulated 
by growth factors and other cellular activators [21,22] and 
to correlate with cell transformation by middle t, v-src and 
abl mutants [23-26]. 
The structural basis for activation of PI 3-kinase by 
protein-tyrosine kinases has been extensively studied. The 
enzyme is a heterodimer of an 85-kDa regulatory subunit 
and a 110-kDa catalytic subunit [27]. The regulatory sub- 
unit contains two SH2 domains, a SH3 domain and a 
region of homology to Bcr [28-30]. The SH2 domains 
mediate association with certain activated protein-tyrosine 
kinases by directly binding to phosphorylated tyrosine 
residues [21,31,32]. The 85 kDa subunit also has two 
proline-rich regions that mediate association with other 
proteins via direct binding to SH3 domains [33,34]. 
The function of PI 3-kinase is not yet clear. Mutations 
in various oncogenes that impair their association with and 
activation of PI 3-kinase also compromise their ability to 
cause cell morphological changes and anchorage-indepen- 
dent cell growth [21,35]. In addition, PI 3-kinase has been 
implicated in various responses to platelet-derived growth 
factor (PDGF), including mitogenesis [36-38], chemotaxis 
[39,40], membrane ruffling [40] and activation of $6 kinase 
[41]. Cytoimmunofluorescence rev als that much of the PI 
3-kinase is bound to intracellular organelles [42]. 
Because of the presence of a potential binding site for 
the SH2 domains of PI 3-kinase in pp125 FAK, we investi- 
gated the possibility that these proteins are associated in 
vivo. Using cytoimmunofluorescence, we show that a frac- 
tion of PI 3-kinase is located in focal adhesion plaques. 
We also shown that PI 3-kinase activity is immunoprecip- 
itated from middle t-transformed fibroblasts by two differ- 
ent anti-FAK antibodies. In addition, glutathione-S-trans- 
ferase fusion proteins of full-length p85, the C-terminal 
SH2 domain from p85 or the SH3 domain from p85 
precipitate pp125 FAK from middle t-transformed cells. A 
phosphopeptide that binds the SH2 domain blocks associa- 
tion with full-length p85 and with the SH2 domain but 
does not block association with the SH3 domain. A pro- 
line-rich peptide that binds to the p85 SH3 domain specifi- 
cally blocks the association with the GST-SH3 domain. 
These results indicate that phosphorylation f pp125 ~AK on 
tyrosine contributes to the recruitment of PI 3-kinase into 
the focal adhesion plaque. 
2. Materials and methods 
2.1. Cells 
NIH 3T3 fibroblasts and V4 cells (polyoma virus mid- 
dle T antigen-transfected NIH 3T3 flbroblasts) were cul- 
tured in DMEM containing 10% FCS in 100-mm dishes 
until they reached 90% confluence. They were switched to 
serum-free medium containing 0.5% albumin 15 h before 
the experiments were performed. Prior to lysis, cells were 
activated 20 min with 10% FCS. After being washed twice 
in cold PBS, two protocols (A or B) were used to solubi- 
lize the cells. 
(A) Either 400/zl or 200/zl of ice-cold lysis buffer (20 
mM Tris, 0.5 M NaC1, 1% Triton, with: 5 /zg/ml Leu- 
peptin, 10 /xg/ml Aprotinin, 1 mM PMSF, 0.2 mM 
sodium vanadate, 50 /xM PAO and 1 mM ZnC12) was 
added and the cells were immediately scraped. 
(B) The cells were treated with trypsin and scraped into 
suspension. Then, the cells were pelleted by centrifugation 
at 1500 rpm for 3 min and washed with cold PBS before 
addition of the lysis buffer (137 mM NaC1, 20 mM Tris 
chloride, 1 mM MgC12, 1 mM CaC12, 10% glycerol, 1% 
NP-40, 5 /xg/ml Leupeptin, 10 /xg/ml Aprotinin, 1 mM 
PMSF, 0.2 mM sodium vanadate, 50 /zl PAO). 
After either procedure A or B, the cells were incubated 
for 30 min at 4°C with constant shaking. The lysates were 
cleared by centrifugation at 15 000 rpm for 10 min and 
filtered through 0.2 /xm filters. Protein concentration was 
then adjusted to 2 mg/ml/sample for immunoprecipita- 
tion. For the experiments with the GST-fusion proteins, the 
concentration was adjusted to 2 mg/ml/sample and then 
2 mg/ml of BSA was added. For the peptide competition 
experiments, the concentration was adjusted to 8 mg/ml 
(+ BSA 2 mg/ml) and 300 /zl were used per sample. 
2.2. Cytoimmunofluorescence 
NIH cells were plated on 12-mm glass coverslips and 
cultured as described. Whole cells were fixed with 4% 
paraformaldehyde for 5 min and permeabilized with PBS 
1% NP40 for 5 min. Ghost cells were prepared by 5 min 
permeabilization in Tris buffer 1% NP40 prior to fixing in 
4% paraformaldehyde for 5 min. Coverslips were incu- 
bated in PBS-I% BSA for 10 rain, primary antibodies for 
30 min followed by secondary antibodies for 30 min. All 
reactions were carried out at room temperature. Coverslips 
were mounted on a Mowiol-DABCO solution and photo- 
graphed on an Olympus BH2 microscope and camera set 
up. 
2.3. Immunoprecipitation a d P I  3-kinase assay 
The lysates, adjusted to 2 mg/ml/sample, were incu- 
bated 3 h with the various antibodies: anti-pp125FAK: 
monoclonal antibody 2A7 or a polyclonal antiserum BC3, 
anti p85-PI 3-kinase, anti-phosphotyrosine (kindly pro- 
vided by Brian Druker) or rabbit anti-mouse immuno- 
globulin (RAM). Then, immune complexes were incubated 
1 h with protein A-Sepharose beads at 4°C with constant 
shaking. The beads were washed at 4°C, three times with 
(PBS + NP 40 1%, vanadate 0.2 mM; PAO 50/zM), twice 
with (LiCI 0.5 M, Tris 0.1 M, pH 7.5, vanadate 0.2 mM) 
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and twice with (Tris 10 raM, pH 7.5, NaC1 100 mM, 
EDTA 1 mM, vanadate 0.2 mM). 
For the precipitation with monoclonal antibody 2A7, 
protein A-Sepharose beads was first incubated with RAM. 
Then, the PI 3-kinase assay was performed as previously 
described [27]. Briefly, this assay was performed on the 
immunoprecipitates by adding sonicated Ptdlns (in Hepes 
10 mM, pH 7.5, EGTA 1 rrdVl; final concentration f lipid 
0.2 mg/ml), [T32p]ATP (20 /xCi) in lipid kinase buffer 
(Hepes 10 mM, pH 7.5, ATP 50/,M, MgCl 2 10 raM) in a 
final volume of 50 /,1. The reaction was incubated for 10 
min at room temperature, and then stopped by adding 80 
/,tl of 1 M HCl. 160 /zl of chloroform/methanol (1:1 
vol./vol.) was added. After mixing and centrifuging to 
separate the phases, the lipid-containing organic layer was 
resolved on oxalate-coated thin-layer chromatography 
plates (Silica Gel 60) developed in chloroform/ 
methanol/water/ammonium hydroxide (630#47/11.3/2). 
The plates were exposed to film and the P-labeled-PIP 
was quantified by using a Phosphorlmager (Biorad) 
2.4. Binding to GST-fusion proteins 
The GST-fusion proteins were prepared as previously 
described [20,34]. In brief, the transformed bacteria were 
grown and the expression of the GST fusion proteins were 
induced by the addition of ]L mM IPTG. Cells were lysed 
by sonication and the fusion proteins were affinity-purified 
with glutathione-Sepharose beads. After 5 washes the beads 
were kept in aliquots as a 50% slurry in NETN (Tris 20 
raM, pH 8, NaC1 100 mM, EDTA 1 mM, NP-40 0.5%, 
DTT 1 mM, Leupeptin 1 /xg/ml, PMSF 1 raM) at -20°C. 
To evaluate the concentration f the GST fusion proteins, 
the proteins were eluted fl:om an aliquot of Sepharose 
beads in SDS-sample buffer and analyzed by 13% SDS- 
PAGE. Various volumes of an eluted-GST at 0.2 mg/ml 
were also loaded and the gel was stained with Coomassie 
blue. The concentration f the V4 lysate was adjusted to 2 
mg/ml and 2 mg/ml of BSA was added. Lysates (1 
ml/sample) were incubated with GST or GST-fusion pro- 
teins (approx. 4 /zg) (GST-SH3-P85, GST-C-SH2-P85, 
GST-N-SH2-P85 or GST-full-P85) at 4°C with constant 
shaking. After 2 h of incubation, the beads were washed as 
described for the immunoprecipitation. 
final volume of 100 /xl. 300 /~1 of the cell lysates adjusted 
to 8 mg/ml (+BSA 2 mg/ml) were then added for a 
further 1 h and then treated as described above. 
2.6. Immunoblots 
Protein in Laemmli buffer containing 5% 2-mercapto- 
ethanol was heated 5 min at 100 ° and proteins were 
resolved in a 7.5% polyacrylamide g l. After transfer, the 
nitrocellulose were blocked with 5% low fat dry milk in 
TBS-T. The nitrocellulose was then incubated 2 h with the 
antibody (in TBS-T + 1% BSA), washed extensively (4 X ) 
with TBS-T and then incubated 45 min with the secondary 
antibody in TBS-T + 1% BSA RAM- or GAR-HRP con- 
jugated. After 3 washes in (TBS-T) and another wash in 
(TBS), the nitrocellulose was developed using the en- 
hanced chemiluminescence system (ECL). 
3. Results 
3.1. Localization of p85-Pl 3-kinase in focal adhesion 
plaques 
Although the majority of p85, as judged by cytoim- 
munofluorescence with a variety of antibodies, is detected 
on punctate structures associated with microtubules [42] 
(also, L. Rameh, unpublished results), a small but signifi- 
cant fraction of the protein co-localizes with FAK at focal 
adhesion plaques (Fig. 1). This localization was detected 
by using anti-phosphoTyr (Fig. 1B) and anti-p85 (Fig. 1A) 
staining of serum-stimulated whole cells. The focal adhe- 
sion plaques can be more clearly detected by anti-FAK 
staining of attached cell ghosts (Fig. 1D,F). In these 
structures, the anti-p85 staining is readily detectable in the 
focal adhesion plaques since the p85 associated with the 
microtubules has been removed (Fig. 1C,E). There does 
not appear to be complete overlap between FAK staining 
(Fig. 1D,F) and p85 staining (Fig. 1C,E), indicating that 
there are regions of FAK concentration that lack p85. 
3.2. Anti-p85 antibodies immunoprecipitate a 125-kDa 
tyrosine-phosphorylated protein 
2.5. Peptide competition assays 
For the competition experiments, the immobilized 
GST-full-p85 or GST-SH3-p85 were preincubated 15 min 
with a phosphotyrosine-peptide containing the optimal se- 
quence for binding to SH2-p85 (RENEpYMPMAPQIH) or 
with a proline-rich-peptide corresponding to the residues 
82-96 of p85a (SPPTPKPRPPRPLP) or with a control 
peptide (WAGGDASGE, fl'om Sigma). These preincuba- 
tions were performed at 4°C with constant shaking in a 
Since FAK and p85 are both detectable in focal adhe- 
sion plaques, we investigated the possibility that PI 3-kinase 
associates with pp125 FAK in NIH 3T3 and polyoma middle 
t-transformed cells. Anti-FAK and anti-p85 antibodies were 
used to immunoprecipitate native proteins from NP-40 
solubilized middle t-transformed cells (V4 cells) and the 
proteins were blotted with an anti-phosphotyrosine anti- 
body. In agreement with previous results observed in 
v-src-transformed cells, the 125-kDa FAK protein was 
significantly phosphorylated on tyrosine as judged by im- 
munoprecipitation with two different antibodies (lanes 2 
and 3, Fig. 2), Also in agreement with previous results 
(unpublished results from Cantley lab), the anti-p85 anti- 
body precipitated several tyrosine-phosphorylated proteins 
from V4 cells. The bands at 55-60 kDa include the middle 
t and pp60 ..... proteins and the band at 85 is the regula- 
tory subunit of PI 3-kinase [43], The identities of the 180 
kDa band and 125 kDa band are not known but the latter 
band comigrates exactly with pp125 FAK in several gel 
systems. It is possible that more than one tyrosine- 
phosphorylated protein migrates at this position of the gel 
and the insufficient sensitivity, in these conditions, of the 
FAK antibodies for blotting have precluded identity of this 
protein as FAK. Blotting of FAK irnmunoprecipitates with 
anti-p85 antibodies have been suggestive but not conclu- 
sive of the presence of PI 3-kinase (not shown). 
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Fig. 1. p85-PI 3-kinase is found in focal adhesion plaques. Serum-stimulated NIH 3T3 cells were fixed with paraformaldehyde, permeabilized with NP40 
and then co-stained with anti-P85 N-terminal/anti rabbit-rhodamine (panel A) and anti-phosphoTyr/anti-mouse-fluorescein (pan l B) antibodies. Ghost 
cells from Quiescent NIH 3T3 cells stimulated with serum were stained with anti P85 C-terminal/anti rabbit-rhodamine (panel C) and anti-pp125FAK/anti 
mouse-fluorescein (panel D) antibodies or anti-P85 N-terminal/anti-rabbit-rhodamine (pa l E) and anti-pp125FAK/anti mouse-fluorescein (panel F) 
antibodies. 
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cells (lane 5). These results indicate that PI 3-kinase 
associates with FAK in transformed cells or serum stimu- 
lated cells. 
The amount of PI 3-kinase activity associated with FAK 
may be significantly underestimated because of a technical 
problem with the experiment. We found that a majority of 
the phosphotyrosine on FAK was lost during the immuno- 
precipitation protocol even in the presence of 0.2 mM 
sodium vanadate. Conditions necessary to prevent signifi- 
cant loss of phosphotyrosine during the immunoprecipita- 
tion (1 mM ZnC12 plus vanadate) resulted in retention of a 
majority of the tyrosine-phosphorylated p85 and pp125 FAK 
proteins in a detergent-insoluble fraction. Thus, in the 
presence of phosphotyrosine phosphatase inhibitors, much 
43 • 
1 2 3 4 5 
Fig. 2. A 125 kDa Tyr-phosphorylated protein co-immunoprecipitates 
with p85. Lysates from V4 cells were subjected to immunoprecipitation 
with non-specific rabbit anti-mouse serum (RAM)(lane 1), mouse anti- 
pp125 FAK (2A7) in the presence of RAM (lane 2), rabbit anti-pp125 FAK 
(BC3) (lane 3) or rabbit anti-p85 (lane 4). The total cell lysate was added 
to lane 5. After resolution of proteins by 7.5% SDS-PAGE under 
reducing conditions, the proteins were transferred to nitrocellulose and 
blotted with an anti-phosphoTyr antibody. The tyrosine-phosphorylated 
protein at 125 kDa comigrates with FAK as judged by blotting with 
anti-FAK antibodies (not shown). 
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3.3. Anti-FAK antibodies immunoprecipitate PI 3-kinase 
activity 
Since PI 3-kinase assays are much more sensitive than 
immunoblots for detecting: the presence of this enzyme, 
anti-FAK immunoprecipitates from polyoma middle t- 
transformed 3T3 cells (V4 cells) were investigated for the 
presence of PI 3-kinase activity. As shown in Fig. 3, both 
anti-FAK antibodies precipitated PI 3-kinase activity 8- to 
20-fold above control antibodies. The fraction of activity 
that co-precipitated with FAK was between 0.2 and 1% of 
the total anti-p85 precipitable activity. This is similar to or 
greater than the amount ound associated with activated 
EGF receptor, insulin receptor or HGF receptor in cells 
over-expressing these receptors [44,45] (also, unpublished 
results) but less than that tbund associated with the PDGF 
receptor or middle t (typically 5-10%). As show in Fig. 4, 
the anti-FAK antibody failed to immunoprecipitate PI 3- 
kinase activity from unstimulated non-transformed 3T3 
cells (lane 2). However, when these cells were stimulated 
with serum, a marked increase in PI 3-kinase activity was 
found in the anti-FAK immunoprecipitate (lane 3). This 
activity was somewhat less than that detected in the V4 
B 
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Fig. 3. Association of PI 3-kinase activity with anti-pp125 FAK immuno- 
precipitates. Lysates from V4 cells were subjected to immunoprecipita- 
tion with non-specific rabbit anti-mouse (RAM)(lane 1), mouse anti- 
pp125 FAK (2A7) in the presence of RAM (lane 2), rabbit anti-pp125 FAK 
(BC3) (lane 3) or rabbit anti-p85 (lane 4). A PI 3-kinase assay was 
performed on the washed immunoprecipitates as described in Section 2. 
Lipid extracts were resolved by thin-layer chromatography, detected by 
autoradiography (panel A) and quantified (Arbitrary Unit AU) by using a 
Biorad PhosphorImager (panel B). These data are representative of three 
experiments. The lipid product was identified as PI 3-kinase on the basis 
of co-migration with the standard and sensitivity of the assay to detergent 
[58]. 
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Fig. 4. Comparison of association of PI 3-kinase activity with anti- 
pp125 FAK immunoprecipitates from V4 and non-transformed cells. Cells 
lysates from either V4 (lanes 4 and 5) or quiescent non-transformed 3T3 
cells (lane 2) or 3T3 cells stimulated with 10% serum (lanes 1 and 3) 
were prepared following procedure A (see Section 2). Then, proteins 
from the lysates were precipitated with non-specific rabbit anti-mouse 
(RAM) (lanes 1 and 4) or with anti-pp125 FAK (2A7) (lanes 2, 3 and 5). A 
PI 3-kinase assay was conducted on each immunoprecipitate s in Fig. 3. 
of the FAK/PI  3-kinase complex may fail to solubilize out 
of the focal adhesion complex. 
3.4. Sub-domains of p85 bind to pp125 FAK 
The possibility that subdomains of the 85 kDa subunit 
of PI 3-kinase can interact with pp125 rAK was investi- 
gated. As shown in Fig. 5, a GST-fusion protein of full- 
length p85 very effectively associated with pp125 rAK from 
V4 cells. The C-terminal SH2 domain bound less well than 
full-length p85 but was more effective than the N-terminal 
SH2 domain. This result is in good agreement with previ- 
ous results, indicating that the C-terminal SH2 domain has 
higher affinity for phosphoTyr-Xxx-Xxx-Met motifs than 
does the N-terminal SH2 domain [46,47]. The C-terminal 
half of pp125 FAK has a sequence (Tyr951-Val-Pro-Me0 
that, if phosphorylated, is predicted to bind with high 
/ 
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Fig. 5. FAK interacts with GST-fusion proteins from p85-PI 3-kinase. V4 
lysates was adjusted to 2 mg protein/ml. Aliquots of 1 ml were incubated 
for 2 h at 4°C with glutathione-agarose immobilized fusion proteins (4/xg 
in each case): lane 1, GST; lane 2, GST-full-p85; lane 3, GST-C-SH2-p85; 
lane 4, GST-N-SH2-p85 and lane 5, GST-SH3-p85. The beads were 
washed and 2 × SDS loading buffer was added. The samples and 100/xl 
of total lysate (lane 6) were separated by 7.5% SDS-PAGE and trans- 
ferred to a nitrocellulose filter. The presence of FAK in the precipitate 
was determined by immunoblot using mouse anti-FAK (2A7) and devel- 
oped with the ECL method. 
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Fig. 6. Inhibition of FAK binding to GST-p85 by specific peptides. (A) 
Immobilized GST-full-p85 was incubated either with 0.1 mM, 0.5 mM or 
1 mM of the proline-rich peptide from p85, SPPTPKPRPPRPLP (lanes 
3-5), or with 0.02 mM, 0.1 mM or 0.2 mM of the PhosphoTyr peptide 
from hamster middle t, RENEpYMPMAPQIH (lanes 7-9), or with a 
control peptide, WAGGDASGE (lane 6) or no peptide (lane 2) for 15 min 
at 4°C with constant shaking. 300/xl of V4 lysate at 8 mg/ml was added 
to each sample for a further 1 h and then the samples were treated as 
described in Fig. 4. B) Immobilized GST-SH3-p85 was incubated either 
with 0.1 mM, 0.5 mM or 1 mM of Proline-rich peptide (lanes 3-5), with 
control peptide (lane 6) or no peptide (lane 2) and then treated exactly as 
in A. 
affinity to the SH2 domains of p85 [20,36,46]. However, 
other motifs of pp125 FAK with lower affinity could medi- 
ate in vitro association with the SH2 domains of p85. 
Interestingly, the SH3 domain of p85 was also effective at 
precipitating pp125 yAK. This SH3 domain has been shown 
to bind with relatively high affinity to two different pro- 
line-rich sequences within p85 itself [34]. Examination of 
the sequence of p125 FAK reveals two proline-rich se- 
quences tarting with Ala 712 (APPKPSRPHYPSP) and 
with Lys 868 (KPDHAAPPKKPPRP). These sequences, 
are 230 and 80 residues N-terminal respectively of the 
Tyr-Val-Pro-Met motif that is predicted to bind the SH2 
domain of p85. 
In order to determine whether the association of p85 
with pp125 FAK is mediated by the SH2 domains, SH3 
domain or both, peptides that bind to these two domains 
were used to complete the interaction. As shown in Fig. 
6A, a phosphopeptide containing the phosphoTyr-Met- 
Xxx-Met motif was very effective at blocking the interac- 
tion of p85 with pp125 FAK, indicating that the SH2 do- 
mains are primarily responsible for mediating p85 interac- 
tions with pp125 FAK. A peptide based on the 82-96 region 
of p85 that binds its own SH3 domain was ineffective at 
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blocking the interaction between p85 and pp125 FA~:, al- 
though it did block the binding of p85 SH3 to pp125 FAI< 
(Fig. 6B). 
4. Discussion 
We have shown that a fraction of PI 3-kinase is found 
in focal adhesion plaques. Localization of p85 in this 
structure correlates with the presence of tyrosine phospho- 
rylated proteins, therefore, more p85 is found in focal 
adhesion plaques of serum stimulates cells when compared 
to quiescent cells. Consistent with this finding, a small 
amount of PI 3-kinase can be detected in anti-FAK im- 
munoprecipitates from serum-stimulated NIH 3T3 or mid- 
dle t-transformed 3T3 cells. Attempts to determine the 
mechanism of association using in vitro reconstitution with 
recombinant proteins reveals that SH2 domains of p85 
complex with tyrosine-pho,;phorylated FAK.
The fraction of these proteins that are associated in vivo 
is difficult to assess. Condi~Eions that stabilize the phospho- 
rylated form of pp125 FAK necessary for the complex se- 
quester both p125 FAK and p85 into a detergent-insoluble 
complex that cannot be examined for co-immunoprecipita- 
tion. About 1% of solubilized p85 co-immunoprecipitates 
with p125 FAK. The actual fraction associated may be much 
larger. It is clear from cytoimmunofluorescence that only a 
minority of anti-85 stainable PI 3-kinase is in focal adhe- 
sion plaques. Consistent with these findings, stimulation of 
platelets with thrombin results in the localization of p85 in 
a Triton-insoluble fraction where pp125 FAK is also found 
[48] (also, unpublished a~i). 
Ours results are consistent with those, recently pub- 
lished, of Chen and Guan showing an association of FAK 
with PI 3-kinase in response to cell adhesion [49] or PDGF 
stimulation [50]. The mechanism of association of 
pp125 FAK and PI 3-kinase is not yet clear and could be 
quite complex. We have shown that in vitro the SH2 
domains of p85 are responsible for association with 
pp125 FAK. Therefore, since the preferred sequence for 
binding to these domain,; is phosphoTyr-Met/Val/Ile- 
Xxx-Met [20,36,46], these data suggest that association of 
FAK and PI 3-kinase is dependent on FAK phosphoryla- 
tion at this site. However, in the cell the association may 
involve additional mechanisms. For example, upon activa- 
tion src-family members bind to pp125 FAK via their SH2 
domains interacting with the phosphoTyr397 Ala-Glu-Ile site 
[5,6]. The SH3 domains of src-family members could then 
bind the proline-rich regions of p85 to bring PI 3-kinase 
into the complex [33,34]. Likewise, such a system, involv- 
ing an adaptor protein (GRB2) to allow association of 
FAK with another protein, namely Sos, was previously 
proposed [8]. A third possible interaction between 
pp125 FAK and PI 3-kinase could include the SH3 domain 
of p85 binding to a proline-rich region of pp125 FAK. In 
vitro, this interaction occurs with the isolated SH3 domain 
of p85 but does not appear to contribute significantly to 
the interaction with full-length p85 (Fig. 6). However, a 
modification of the native PI 3-kinase might expose the 
SH3 domain for such an interaction. A possible scenario is 
that SH3 domains of src-family kinases associate with the 
proline-rich domains of p85 and the phosphotyrosine site 
of FAK associates with the SH2 domains of p85 to form a 
tight ternary complex. 
Phosphopeptides containing the consensus sequence 
phosphoTyr-Met/Val/Ile-Xxx-Met canactivate the puri- 
fied PI 3-kinase [47,51-53]. Thus, in vivo, the binding of 
FAK to PI 3-kinase could activate PI 3-kinase. Moreover, 
the translocation of PI 3-kinase, consecutive tothe associa- 
tion, localize this enzyme at a specific region of the 
membrane where Ptdlns-3,4,5-P3 would be generated. 
Consistent with this model, fibrinogen-binding to aiib-/33 
integrin induces FAK phosphorylation a d activation [17] 
but also PI 3-kinase activation [54], suggesting that PI 
3-kinase may be involved in integrin outside-in signaling. 
We have found that the lipid products of PI 3-kinase 
can activate the calcium-independent protein kinase C 
isotypes (PKC 3, PKC e and PKC~7) [55]. It is possible that 
recruitment of specific PKC isotypes to focal adhesion 
plaques, due to activation of PI 3-kinase in this region, is 
involved in FAK-mediated responses. Recently, we 
demonstrated that in platelets production of Ptdlns-3,4-bis- 
phosphate is responsible of prolonged phosphorylation f
the major PKC substrate, pleckstrin [56]. Moreover, we 
have shown that PI 3-kinase activation is necessary to 
sustain platelets aggregation by maintaining anb-/33 inte- 
grin in the activating conformation [57]. This suggests that 
PI 3-kinase may also be involved in integrin inside-out 
signaling. 
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